SCHEMBL23736207

SCHEMBL23736207

C/C=C/Cc1cnc(C)c(CCC)n1

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.33
NOS3 P29474 1/20 0.31
NOS1 P29475 1/20 0.31
NOS2 P35228 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL511539 0.81 NOS3 (0.37) HSP90AA1NOS3NOS1NOS2
SCHEMBL16548309 0.72 NOS3 (0.36) HSP90AA1NOS3NOS1NOS2
SCHEMBL30689655 0.71 HSP90AA1 (0.36) HSP90AA1NOS3NOS1NOS2
SCHEMBL10307332 0.71 HSP90AA1 (0.36) HSP90AA1NOS3NOS1NOS2
SCHEMBL293007 0.70 NOS2 (0.41) NOS2
SCHEMBL23736206 0.69 HSP90AA1 (0.31) HSP90AA1
SCHEMBL30689642 0.69 HSP90AA1 (0.31) HSP90AA1
SCHEMBL23736208 0.69 HSP90AA1 (0.31) HSP90AA1
SCHEMBL5230567 0.68 MAPKAPK2 (0.40) HSP90AA1
SCHEMBL5228304 0.68 HSP90AA1 (0.37) HSP90AA1NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11891364-B2 Methods of selectively forming substituted pyrazines R.J. REYNOLDS TOBACCO COMPANY (US) 2024-02-06 US claimed
CN-110637012-B Method for selectively forming substituted pyrazines R.J.雷诺兹烟草公司 2023-11-24 CN claimed
US-20210403437-A1 METHODS OF SELECTIVELY FORMING SUBSTITUTED PYRAZINES REYNOLDS TOBACCO CO R (US) 2021-12-30 US claimed
US-11091446-B2 Methods of selectively forming substituted pyrazines R.J. REYNOLDS TOBACCO COMPANY (US) 2021-08-17 US claimed
US-11891364-B2 Methods of selectively forming substituted pyrazines R.J. REYNOLDS TOBACCO COMPANY (US) 2024-02-06 US disclosed
US-20210403437-A1 METHODS OF SELECTIVELY FORMING SUBSTITUTED PYRAZINES REYNOLDS TOBACCO CO R (US) 2021-12-30 US disclosed
US-11091446-B2 Methods of selectively forming substituted pyrazines R.J. REYNOLDS TOBACCO COMPANY (US) 2021-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11891364-B2 Methods of selectively forming substituted pyrazines KHK, HK2, HK1 HSP90AA1 1354/4885NOS3 2076/4885NOS1 2168/4885
US-11091446-B2 Methods of selectively forming substituted pyrazines KHK, HK2, HK1 HSP90AA1 1354/4885NOS3 2076/4885NOS1 2168/4885
US-20210403437-A1 METHODS OF SELECTIVELY FORMING SUBSTITUTED PYRAZINES KHK, HK2, HK1 HSP90AA1 1354/4885NOS3 2076/4885NOS1 2168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.